SCHEMBL534254

SCHEMBL534254

O=C(O)Cc1ccccc1OC(F)(F)F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 2/20 0.58
AKR1B1 P15121 1/20 0.50
CHRM1 P11229 1/20 0.48
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
RXRG P48443 1/20 0.48
VNN1 O95497 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
FFAR1 O14842 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
CAMK2A Q9UQM7 2/20 0.44
PSMB5 P28074 1/20 0.44
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29782307 1.00 CXCL8 (0.58) CXCL8AKR1B1CHRM1RXRARXRB
Hydrochloric Acid SCHEMBL2530814 0.98 CXCL8 (0.57) CXCL8AKR1B1CHRM1RXRARXRB
SCHEMBL29718710 0.87 CXCL8 (0.49) CXCL8AKR1B1CHRM1RXRARXRB
SCHEMBL6963700 0.86 VNN1 (0.47) CXCL8RXRARXRBRXRGVNN1
SCHEMBL31736338 0.85 CXCL8 (0.46) CXCL8AKR1B1CHRM1RXRARXRB
SCHEMBL8088589 0.85 CXCL8 (0.54) CXCL8AKR1B1CHRM1VNN1L3MBTL1
SCHEMBL6195827 0.84 L3MBTL1 (0.57) CXCL8RXRARXRBRXRGVNN1
SCHEMBL10565876 0.84 GRIN2B (0.48) CXCL8RXRARXRBRXRGVNN1
SCHEMBL2530811 0.84 VNN1 (0.46) CXCL8RXRARXRBRXRGVNN1
SCHEMBL14661063 0.83 P2RX7 (0.50) CXCL8AKR1B1CHRM1RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346778-A1 FLUORINE-CONTAINING COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-11-13 US disclosed
EP-4079724-B1 2-(2-CHLOROPHENYL)-N-(5-SULFAMOYLISOQUINOLIN-7-YL)ACETAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS P2X4 ANTAGONISTS FOR THE TREATMENT OF E.G. URINARY TRACT DISEASES WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) 2025-11-12 EP disclosed
US-20250340752-A1 FLUORINATED POLYMER DAIKIN INDUSTRIES, LTD. (JP) 2025-11-06 US disclosed
US-20250333902-A1 FLUORINE-CONTAINING COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-10-30 US disclosed
EP-4574872-A1 FLUORINE-CONTAINING COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-06-25 EP disclosed
EP-4538304-A1 FLUORINATED POLYMER DAIKIN INDUSTRIES, LTD. (JP) 2025-04-16 EP disclosed
EP-4516773-A1 FLUORINE-CONTAINING COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-03-05 EP disclosed
CN-118239953-A Compounds for the treatment of PI3K gamma mediated diseases and uses thereof 中国科学院合肥物质科学研究院 2024-06-25 CN disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 CN disclosed
WO-2024067560-A1 SULFONAMIDE COMPOUND AND MEDICAL USE THEREOF 中国药科大学 2024-04-04 WO disclosed
EP-1851204-A1 NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR SmithKline Beecham Corporation (US) 2007-11-07 EP disclosed
WO-2007067575-A2 PROCESS FOR PREPARING SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES WYETH (US) 2007-06-14 WO disclosed
US-20070129377-A1 Process for Preparing Substituted Aryl Cycloalkanol Derivatives WYETH (US) 2007-06-07 US disclosed
WO-2006091592-A1 NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2006-08-31 WO disclosed
US-20060106035-A1 Phenyl-substituted pyrazolopyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-05-18 US disclosed
US-20050026929-A1 Novel phenyl derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-02-03 US disclosed
CN-1575191-A Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors PFIZER PROD INC (US) 2005-02-02 CN disclosed
WO-2003090680-A2 NOVEL PHENYL DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2003-11-06 WO disclosed
US-6090805-A Tocolytic oxytocin receptor antagonists MERCK & CO., INC. (US) 2000-07-18 US disclosed
US-5968938-A Piperazine oxytocin receptor antagonists MERCK & CO., INC. (US) 1999-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129377-A1 Process for Preparing Substituted Aryl Cycloalkanol Derivatives CYP1A2, CYP3A7, CYP3A43 CXCL8 3980/4885AKR1B1 368/4885CHRM1 2844/4885
US-20050026929-A1 Novel phenyl derivatives as inducers of apoptosis BAX, BAD, CASP3 CXCL8 3512/4885AKR1B1 1510/4885CHRM1 4787/4885
US-20060106035-A1 Phenyl-substituted pyrazolopyrimidines P2RX4, P2RY4, P2RX5 CXCL8 1473/4885AKR1B1 3329/4885CHRM1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.